ArticleDiscover oncology2025
Characterization of hepatocarcinoma cells: lymphatic metastasis potential through enhanced production, expression, and secretion along the VEGF-C/D-VEGFR-3/NRP-2 axis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn vitro and in vivo analyses were conducted to examine the correlations between the production, expression, and secretion of the VEGF-C/D-VEGFR-3/NRP-2 axis and various levels of lymphatic metastatic potential in murine hepatocellular carcinoma cells.
methodsQuantitative real-time PCR, western blotting, cytoimmunofluorescence, immunohistochemistry, and enzyme-linked immunosorbent assay were employed to assess the expression and secretion of the VEGF-C/D-VEGFR-3/NRP-2 axis at the gene, protein, cytological, and histological levels.
resultsIn both in vitro and in vivo experiments, the ligands VEGF-C/D and receptors VEGFR-3/NRP-2 were primarily localized in the cytoplasm or cell membrane of hepatocarcinoma F/P cells with high/low lymphatic metastatic potentials, and in normal hepatocytes, respectively. The production and expression levels of the VEGF-C/D-VEGFR-3/NRP-2 axis in F/P cells were significantly higher than those in normal liver cells. Additionally, the production and expression of this axis were higher in F cells compared to P cells (P < 0.01). Notably, within both F/P cells, the production and expression levels of VEGF-C and VEGFR-3 were lower than those of VEGF-D and NRP-2 (P < 0.05). However, the secretion of VEGF-C exceeded that of VEGF-D in the supernatant of cultured cells and in the serum of tumor-bearing mice (P < 0.01). Interestingly, the ratio of VEGF-C/D in F cells was significantly higher than that in P cells and normal hepatocytes. Moreover, the ratio of VEGF-C/D was notably elevated in the supernatant of tumor cells and serum from tumor-bearing mice, as determined by ELISA, compared to that in tumor cells and tissues assessed using other technologies (P < 0.01).
conclusionThe significant co-production, co-expression, and co-secretion of the VEGF-C/D-VEGFR-3/NRP-2 axis are distinctive features of hepatocarcinoma cells, particularly those with a heightened potential for lymphatic metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.